Monthly Archives: novembre 2016

//novembre

TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.

Roland Kratzer, et al. AASLD & Hepatology, October 2016 - [...]

By |2019-07-02T12:00:45+02:00novembre 14th, 2016|Publication, TG1050|Commentaires fermés sur TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.
Read More
Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166 67405 Illkirch Graffenstaden Cedex - France | Tel. : + 33 (0) 3 88 27 91 00 - Fax. : + 33 (0) 3 88 27 91 11
© 2019 Transgene - All rights reserved
Mentions légales - Crédits